Baseline PSA Screening and Long-Term Prostate Cancer Risk

​Baseline levels of prostate-specific antigen (PSA) at age 55 to 60 are correlated with men's long-term risk of developing clinically significant prostate cancer, according to a secondary analysis of long-term follow-up results from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.Once broadly accepted as a tool for the early detection of prostate cancer, PSA screening has become controversial in recent years due to issues of overdiagnosis and overtreatment of slow-growi...
Continue reading

Progress in Metastatic Castration-Sensitive Prostate Cancer: Andrew J. Armstrong, MD, MSc

Last week, Andrew J. Armstrong, MD, MSc, lead researcher of the phase 3 ARCHES trial, spoke with i3 Health about the recent approval of enzalutamide (Xtandi®, Astellas Pharma Inc.) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and the variety of options that are now available for the treatment of metastatic hormone-sensitive disease. In this second installment, Dr. Armstrong discusses the ongoing evolution of therapeutic strategies in mCSPC and shares his advice fo...
Continue reading

Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer: Andrew J. Armstrong, MD, MSc

​The FDA recently added a new approval of enzalutamide (Xtandi®, Astellas Pharma Inc.) for the treatment of metastatic castration-sensitive prostate cancer, based on data from the ARCHES and ENZAMET trials. In this interview with i3 Health, Andrew J. Armstrong, MD, MSc, lead researcher of the phase 3 ARCHES trial, discusses the approval's significance and compares the variety of options that are now available for the treatment of metastatic hormone-sensitive disease.What are the greatest challen...
Continue reading

Enzalutamide Approval: Metastatic Castration-Sensitive Prostate Cancer

The FDA has now approved enzalutamide (Xtandi®, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC).Patients with mCSPC, who comprise up to 5% of US patients with prostate cancer, have metastatic disease and either have not yet received or are continuing to respond to hormone therapy. Androgen deprivation therapy (ADT) has been considered the standard of care for mCSPC. After experiencing an initial treatment response, most patients who receive ADT alo...
Continue reading

High Dairy Consumption Increases Prostate Cancer Risk

Among cancers that affect men, prostate cancer is the most common and carries the second highest rate of mortality. How does diet play a role in this widespread public health concern, which affects 11.6% of American men at some time in their lives? A new literature review published in The Journal of the American Osteopathic Association reports that consuming high amounts of dairy may increase prostate cancer risk, while consuming high amounts of plant-based foods may decrease risk."Previous stud...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.